Tags : Obstructive Hypertrophic Cardiomyopathy


MyoKardia’s Mavacamten Receives the US FDA’s Breakthrough Therapy Designation for

Shots: The US FDA has granted BTD to mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy (HCM) In May’2021, MyoKardia reported the results of the P-III EXPLORER study that demonstrated the robust treatment effect, with patient responses to treatment, including reductions in symptoms, improvements in cardiac function and reduction or elimination of the obstruction […]Read More